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Insulin signalling and its negative regulators in 
aging-associated diseases 
 
The insulin/insulin-like signalling pathway is highly 
conserved throughout the animal kingdom. Whereas its 
predominant role in mammals is the control of 
metabolic homeostasis and its deregulation leads to the 
development of diabetes mellitus, lowering 
insulin/insulin-like signalling in c. elegans, d. 
melanogaster and m. musculus has been implicated in 
lifespan extension [1-5].  
 
The anabolic peptide hormone insulin is secreted from 
the pancreas in response to an increase of blood glucose 
concentrations. It acts on the liver to reduce hepatic 
glucose output and it promotes glucose and lipid uptake 
into peripheral tissues such as adipose tissue and 
skeletal muscle. Binding of insulin or insulin-like 
peptides to their receptor leads to recruitment of insulin 
receptor substrate (IRS) proteins, subsequently 
activating two major signalling branches: the 
phosphatidylinositol 3 kinase (PI3K)-pathway and the 
mitogen-activated  protein kinase  (MAPK)-pathway  [6,  
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7]. PI3K activity mediates activation of the kinase AKT,  
which phosphorylates and thereby deactivates forkhead 
transcription factors (FOXOs). FOXOs are 
transcriptional regulators of genes involved in 
metabolism and growth [8]. Activation of the 
PI3K/AKT/FOXO axis mediates many of insulin’s and 
insulin-like peptides’ effects, including e.g. regulation 
of growth, glucose/fat metabolism, stress response and 
lifespan (Figure 1) [9]. Besides the expression and 
activation of this pathway in peripheral organs, the 
insulin/insulin-like signalling machinery is also 
expressed and active in the central nervous system 
(CNS) where it regulates fertility and body weight [10-
12]. Furthermore, it was recently demonstrated that 
insulin action in the CNS also controls peripheral 
glucose and fat metabolism [13-15].  
 
In the last decade, several studies have demonstrated 
that central as well as peripheral insulin signalling can 
be drastically impaired by a variety of obesity- and/or 
aging-associated parameters such as hyperlipidemia, 
hyperglycemia, endoplasmatic reticulum (ER) stress 
and inflammation [16-19]. Following this, the incidence  
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Abstract: Activation of stress‐kinase signaling has recently been recognized as an important pathophysiological mechanism
in the development of diet‐induced obesity, type 2 diabetes mellitus and other aging‐related pathologies. Here, c‐Jun N‐
terminal  Kinase  (JNK)  1  knockout  mice  have  been  shown  to  exhibit  protection  from  diet‐induced  obesity,  glucose
intolerance, and insulin resistance. Nonetheless, the tissue‐specific role of JNK1‐activation in the development of the
metabolic syndrome has been poorly defined so far. Recently, it was demonstrated that JNK1 signaling plays a crucial role
in the central nervous system (CNS) and in the pituitary to control systemic glucose and lipid metabolism partially through
regulation of hormones involved in growth and energy expenditure. 
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mellitus and obesity has created an urgent necessity to 
define the mechanisms underlying energy intake and 
expenditure, and to identify molecular targets for 
pharmacological intervention. 
   
JNK1 and aging-associated diseases 
 
In 2002, the group of Gökhan Hotamisligil revealed that 
mice deficient for the stress mediator c-Jun N-terminal 
Kinase (JNK) 1 are protected from the development of 
high fat diet-induced obesity and glucose intolerance, as 
well as insulin resistance [20]. Nonetheless, it remained 
unclear, in which tissue(s) JNK1 might act to impair 
energy and glucose homeostasis under conditions of 
diet-induced obesity.  
 
The family of JNK kinases can not only be activated by 
cytokines, but also by endoplasmatic reticulum (ER) 
stress and hyperlipidemia, all of which are elevated in 
obesity  and/or  diabetes  mellitus  [21].  Previous  data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
indicated that upon activation, JNK1 mediates 
inhibitory serine phosphorylation of IRS proteins, 
thereby impairing insulin action [22]. Interestingly, it 
was recently reported that mutation of the most 
frequently investigated JNK1 phosphorylation site, 
Ser307, augments (and not blocks) insulin resistance in 
obese mice, possibly pointing to either adaptive 
mechanisms during development or additional parallel 
pathways by which JNK1 can affect metabolism [23].  
  
JNK1 and CNS insulin sensitivity 
 
In the last year, JNK1 has been conditionally 
inactivated in several peripheral classically insulin-
sensitive tissues including adipose tissue, muscle and 
liver [24-26] (Figure 1). Nevertheless, none of these 
mouse models fully recapitulated the protection from 
obesity and diabetes observed in conventional knockout 
mice opening the possibility that JNK1 activation also 
in the CNS may contribute to its effects on energy and 
glucose metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Insulin‐like signalling plays a central role in
growth, metabolism and the aging process. Insulin,
derived  from  pancreatic  beta‐cells  in  mammals  or
insulin‐like  peptides  derived  from  neuroendocrine
cells  in  invertebrates  signals  via  binding  to  and
activation of the membrane bound receptors. This
event  subsequently  activates  PI3K,  which  through
phosphorylation  of  membrane  lipids  (phosphor‐
inositides)  regulates  activity  of  the  downstream
kinase AKT. AKT eventually phosphorylates forkhead
transcript‐tion  factors  such  as  FOXO1,  which  are
then  exported  from  the  nucleus  and  degraded.
FOXOs regulate transcription of many genes involved
in  glucose  and  lipid  metabolism,  growth,  stress
response  and  the  aging  process.  Thus,  insulin‐like
signalling  is  able  to  control  all  of  these  processes
through  FOXO  regulation  and  other  signalling
cascades,  in  the  end  impinging  on  crucial
physiological  processes  and  lifespan  itself.
Nonetheless,  chronic  intake  of  energy‐dense  food
coupled  with  little  physical  activity  leads  to
hyperlipidemia  and  hyperglycemia,  which  through
several  mechanisms  (including  JNK1  activation)
reduce cellular insulin sensitivity, thereby disrupting
metabolic homeostasis. 
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 JNK activation in the hypothalamus during obesity 
development has been linked to endoplasmatic 
reticulum stress, inflammation, or hyperlipidemia [17, 
27-29]. Notably, during our studies of lipid-induced 
hypothalamic leptin resistance, we observed that intra-
cerebroventricular (icv.) injection of saturated fatty 
acids such as palmitate, induced activation of 
hypothalamic IKK, whereas activation of JNKs was not 
readily detectable in vivo [30]. To firmly address the 
question if JNK1 activation in the CNS will give rise to 
dysfunctional energy homeostasis, mice lacking JNK1 
in all neurons (called JNK1
ΔNes) were generated by 
crossing mice with a loxP-flanked JNK1 allele with 
those harbouring a Nestin-Cre gene, which is generally 
used to ablate a gene of interest in neurons and 
astrocytes in the CNS [10, 31]. In line with previous 
studies, JNK1 ablation in the CNS did not affect leptin 
sensitivity, independent of route of administration 
(intraperitoneal or icv.). Thus, it was asked if JNK1, in 
line with its putative role in regulating peripheral insulin 
sensitivity,  would  also  affect insulin  signalling  in  the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNS, which is crucial for energy homeostasis [10, 13, 
14]. JNK1
ΔNes  mice were highly sensitive to the 
anorectic effect of centrally applied insulin, even when 
given at doses that had no effect on control mice [31]. 
In line with the notion that insulin affects body weight 
and glucose homeostasis mainly by its action in the 
hypothalamus [32], we demonstrated that high fat diet-
fed JNK1
ΔNes  mice remained insulin sensitive in the 
hypothalamus [31]. This has also been independently 
demonstrated recently in conventional JNK1 knockout 
mice [33]. These data indicate that JNK1 ablation in the 
CNS retains hypothalamic insulin signalling under 
conditions of positive energy balance. Nonetheless, it is 
not clear if this effect is solely derived from lack of JNK1 
in hypothalamic neurons, or indirectly mediated by other, 
JNK1-deficient extra-hypothalamic neuron populations 
with synaptic connections onto hypothalamic neurons. 
Thus, generation of mice with JNK1 deficiency in 
specific hypothalamic neuron populations will help to 
understand the cell-type specific role(s) of JNK1 in the 
hypothalamus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. JNK1 represents a crucial regulator for a 
wide  spectrum  of  physiological  processes.  In  the 
white adipose tissue, JNK1 has been demonstrated to 
regulate  expression  of  interleukin  6,  which  upon 
release into the circulation may act on the liver to 
decrease  hepatic  insulin  sensitivity.  Hepatic  JNK1 
action  may  downregulate  insulin  degradation,  thus 
improving  insulin  half‐life,  and  protecting  from 
steatosis.  JNK1  action  in  the  skeletal  muscle  does 
impair  local  insulin  sensitivity,  although  systemic 
glucose  homeostasis  is  mostly  unaffected.  In  the 
central nervous system, JNK1 is a negative regulator 
of  insulin  sensitivity,  the  thyroid  axis  and  growth, 
although  the  exact  neuron  populations  mediating 
these effects have not been defined yet.  
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During metabolic phenotyping, we noticed increased 
energy expenditure in JNK1
ΔNes  mice, even when 
corrected for lean body mass [31]. Accordingly, we 
found increased circulating levels of the thyroid 
hormone thriiodothyronine (T3), in the presence of 
elevated concentrations of its releasing hormone, 
namely thyroid stimulating hormone (TSH), a finding 
which was independently reported by Roger Davis and 
colleagues [31, 34]. However, hypothalamic expression 
of thyroid releasing hormone (TRH), which itself 
represents the upstream regulator for expression and 
release of TSH in the pituitary, was unchanged [31].  
 
While Nestin-Cre mice have been widely used for pan-
neuronal (and astrocyte-specific) ablation of genes, 
Nestin is also expressed in a stem cell population in the 
pituitary [35]. Thus, the deleted JNK1 allele was also 
detected in pituitaries of JNK1
ΔNes mice, indicating that 
the change in TSH expression and subsequent T3 may 
be due to a pituitary-autonomous effect (31]. Along this 
line, the expression of the receptor for TRH, TRHR, 
was increased by JNK inhibition in pituitary cells in 
vitro, akin to the increased expression of TRHR in 
pituitaries of JNK1
ΔNes mice in vivo [31]. 
 
Although energy expenditure was increased in JNK1
ΔNes 
mice, body fat mass was not changed compared to 
controls, indicating that JNK1
ΔNes  mice were not 
protected from obesity itself, at least during the first 
four months of age [31]. On the other hand, JNK1
ΔNes 
mice demonstrated reduced body weight either on 
normal chow diet (ND) or on HFD. Thus, it was asked 
whether reduced somatic growth may account for the 
reduced body weight. Indeed, activity of the growth 
hormone (GH) – insulin-like growth factor (IGF) 1 axis, 
which controls somatic growth, was reduced [31, 36].  
 
Does JNK1 inhibition mimic caloric restriction? 
 
When exposed to HFD, JNK1
ΔNes  mice not only 
demonstrated protection against systemic glucose 
intolerance and insulin resistance, but also showed 
reduced hepatic steatosis, and importantly, an anti-
inflammatory gene expression pattern in the adipose 
tissue [31].  
 
So far, a major intervention known to prolong life (and 
protect against the plethora of aging-associated 
diseases) is caloric restriction (CR). Strikingly, CR 
itself reduces circulating levels of GH in rodents, and 
inhibition of this decrease may negate the beneficial 
effects of CR, while mice with mutations in this 
pathway show longer life span as well as protection 
against systemic insulin  resistance [37-40].  Notably,  it  
is only poorly understood, how CR regulates the GH-
IGF1 axis on a molecular level. Upon HFD, JNK 
activity is increased both in the hypothalamus, but 
strikingly also in the pituitary of mice, indicating that 
JNK1 might directly regulate the GH-IGF1 axis in these 
tissues. In addition, it has been shown that overfeeding 
increases somatic growth, and HFD increases naso-anal 
length, in accordance with increased expression of 
growth hormone releasing hormone receptor (GHRHR) 
in the pituitary [31]. Thus, we speculate that JNK1 
might act as a sensor for nutrients, and thus regulate 
both energy expenditure and growth in accordance with 
energy levels.  
 
JNK activation upon obesity may also be interpreted as 
a stress-resolving response and have beneficial effects 
under specific circumstances. Thus, JNK-mediated 
regulation of forkhead transcription factors offers 
protection from cellular stress, at least in invertebrates 
[41, 42]. Furthermore, signal duration, strength and 
spatio-temporal distribution may play a role for the net 
outcome of JNK activation. Eventually, it seems 
possible that JNK1 regulates either growth or thyroid 
axis, indirectly affecting one another. Further analysis 
of cell type-specific JNK1 knockout mice will help to 
define the roles of this stress kinase in the 
pathophysiology of obesity, diabetes mellitus and other 
aging-related diseases. 
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